(L-R) Peter Rohweder, Kevan Shokat, Ziyang Zhang, Daniel Green, Charly Craik

The sci­en­tist who pi­o­neered KRAS drugs has a new idea about mak­ing them more pow­er­ful

It’s on­ly been nine years since Ke­van Shokat’s group at the Uni­ver­si­ty of Cal­i­for­nia, San Fran­cis­co pub­lished the sem­i­nal pa­per break­ing the “un­drug­gable” spell thought to en­snare KRAS, one of the most com­mon onco­genes. In less than a decade — break­neck speed by drug de­vel­op­ment stan­dards — the space went from ut­ter­ly bar­ren to hav­ing one ap­proved drug, plus a close ri­val ready to duke it out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.